Imagine growing a tiny, working version of a human organ on a small chip to test new medicines. Instead of relying on animals, which often react differently than people, these chips mimic how our bodies actually work. It's like having a high-tech dress rehearsal for a drug before it ever reaches a patient.
Pharmaceutical companies face high drug failure rates and high costs due to poor predictability of animal models. Hospitals lack precise tools to determine which specific cancer treatments will work for individual patients.
The CubiX platform, consisting of a Microfluidic Perfusion Lid (MPL), the Hydroflat, and a control unit, along with a validated protocol database.
If you are a drug discovery firm dealing with high attrition rates in preclinical trials — this project developed the CubiX platform that improves the predictability of drug effects on humans. This helps reduce overall development times and costs by replacing animal tests.
If you are a clinic dealing with the need to identify which patients will respond to specific cancer treatments — this project developed a companion diagnostic tool (CubiX CDx) that guides medical treatments based on patient-specific organoids.
If you are a CRO dealing with the lack of reproducible biological protocols for 3D cell cultures — this project developed a validated protocol database and the CubiX control unit to standardize results and improve reliability.
Based on available project data, specific pricing and cost details are not provided.
The project addresses industrial bottlenecks by ensuring compatibility with standard multiwell plate formats and providing a validated protocol database for standardization.
The core innovations, including the Microfluidic Perfusion Lid, Hydroflat, and Cubix control unit, have been patented in Europe and the US.
It leverages the FDA Modernization Act 2.0 (2022) and 3.0 (Dec 2024), which allow drug candidates to be submitted without animal testing.
The company targets the preclinical drug development market (CubiX RUO) by 2026 and the precision medicine market (CubiX CDx) by 2030.
The project is led by a single SME, Cherry Biotech from France, representing 100% of the consortium. This lean structure indicates a focused industrialization effort by a company that already holds patents in the US and EU and has established relationships with hospital and pharma KOLs.
Contact Cherry Biotech (France) regarding CubiX platform licensing
Contact us to explore partnerships with Cherry Biotech for precision oncology
